© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Grace Halsey
Articles
Machine Learning Identifies Risk Factors for Severe Cognitive Decline During Menopause
January 16, 2025
The effective approach to identifying risk for the disruptive cognitive issues holds promise for development of early intervention to mitigate decline.
CAH Update: High-Level Examination of Condition Published in Expert Review of Endocrinology & Metabolism, Neurocrine Announces
January 16, 2025
"Glucocorticoid therapy in classic congenital adrenal hyperplasia: traditional and new treatment paradigms," offers an in-depth look at the disorder and promising therapies.
GLP-1/GIP Dual Agonist HRS9531 Shows Promising Phase 2 Data for Obesity Management
January 15, 2025
More than half of study participants receiving the dual incretin agonist had weight loss of 20% or greater, with no evidence of a plateau and only mild AEs.
The Future of Migraine Care: 3 Wishes for Patients from Leading Neurologist and Researcher Peter McAllister, MD
January 15, 2025
Peter McAllister, MD,
Annual Incidence of Dementia in US Will Double by 2060, Reaching 1 Million Cases
January 15, 2025
Annual incidence of dementia will double in White adults and triple among Black adults. The updated estimates place the lifetime risk of developing dementia after age 55 at 42%.
Neurotoxins, Biomarkers, and Migraine Advocacy: One Neurologist's Thoughts on Focus in 2025
January 14, 2025
Neurologist and clinical investigator Peter McAllister, MD, is eager to make progress in research on diagnosis and treatment and to hear more patient voices.
The FDA Accepts Eisai BLA for Lecanemab Subcutaneous Maintenance Dosing in Adults with Alzheimer Disease
January 14, 2025
Weekly SC injection of lecanemab is expected to maintain clinical and biomarker benefits reached during the IV initiation phase. The PDUFA date is Aug 31, 2025.
New Long-Term Data Suggest Continued Blarcamesine Efficacy in Alzheimer Disease Up to 4 Years
January 14, 2025
Blarcamesine significantly slowed progression of both cognitive and functional decline, with treatment initiated earlier in disease process more effective than that initiated later.
Vertex on the Verge of Breakthrough for Nonopioid Pain Management as NOPAIN Act Takes Effect
January 13, 2025
Suzetrigine, the investigational selective NaV1.8 pain signal inhibitor, with a PDUFA date of Jan 30, could become a first-in-class nonopioid analgesic.
In Migraine Research, Placebo Effect is Increasingly Reaching Parity with Study Drug Impact: Experts Say, "What?"
January 13, 2025
Migraine expert Peter McAllister, MD, a long-time principal investigator for migraine studies, wonders if study design in this area needs to be re-evaluated.